Completed the development of the oncolytic virus M1-c6v1
Established pilot technique
2017Established the pilot technique of oncolytic virus M1-c6v1
M1–VCP inhibitor combination therapy
Enhances specificity, cytotoxicity or immune-stimulating potential of the virus. Accumulation of unfolded proteins during virus replication leads to a transcriptional/ translational response known as the unfolded protein response (UPR), which might counteract the antitumor effect of the oncolytic virus.
CMC, non-clinical and clinical of M1-c6v1 granted
The CMC, non-clinical and clinical of M1-c6v1 was granted by the projects titled 13th Five-Year Major New Drug Creation Project, Leading Team for entrepreneurship in Guangzhou, Guangdong Province and Pioneering talents project of Guangzhou Development Zone, Guangdong Province.
Applied for clinical trials of M1-c6v1 in China, United States and Australia
Virotech starts the clinical trial application of oncolytic virus M1-c6v1 in China, United States and Australia.
ZAP detection kit registered as Class I Medical Device
Zinc finger antiviral protein (ZAP) detection kit (IHC) for the companion diagnostics of oncolytic virus M1 is registered as a Class I Medical Device.
M1 targets ZAP-defective human cancers
Zinc-finger antiviral protein (ZAP) Deficiency Is Necessary for the High Tumor Specificity of M1. Tumor-Selective Replication of M1 Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in Cancer Cells.
Virotech is located in Guangzhou high-tech industrial development zone science city
Guangzhou International Business Incubator G District 416--428,No.3, Langyue Rd, Science Park